Profile
BCLI VRTX ALNY REGN ARGX SGEN
Company Name Brainstorm Cell Therapeutics Inc. Vertex Pharmaceuticals Incorporated Alnylam Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc. argenx SE Seagen Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $7.47M $100.41B $60.32B $58.82B $48.74B $43.15B
Employees 0.03K 6.10K 2.23K 15.16K 1.60K 3.26K
CEO Chaim Lebovits Reshma Kewalramani FASN, Yvonne L. Greenstreet Leonard S. Schleifer Timothy Van Hauwermeiren EMBA, David R. Epstein
Ratings
BCLI VRTX ALNY REGN ARGX SGEN
Quant Rating Score 2 3 1 4 3 3
Quant Rating Sell Neutral Strong Sell Buy Neutral Neutral
Trading
BCLI VRTX ALNY REGN ARGX SGEN
Last Close $0.69 $412.22 $469.36 $572.6 $812.95 $228.74
High 52 $2.48 $516.74 $482.13 $1016.53 $812.95 $228.74
Low 52 $0.55 $366.54 $224.58 $482.92 $532.27 $228.74
Price vs. 52 Week High -72.18 % -20.23 % -2.65 % -43.67 % 0 % 0 %
Price vs. 52 Week Low 25.45 % 12.46 % 108.99 % 18.57 % 52.73 % 0 %
Total Return
BCLI VRTX ALNY REGN ARGX SGEN
1 Month Return -8.67 % 4.83 % 1.78 % -0.02 % 7.44 % 0 %
3 Month Return -42.5 % -11.2 % 50.83 % 4.52 % 46.45 % 0 %
6 Month Return -9.21 % -17.64 % 103.34 % 2.63 % 34.36 % 0 %
9 Month Return -66.34 % -2.84 % 86.99 % -18.6 % 22.21 % 0 %
YTD Return -69.6 % 2.36 % 99.46 % -19.62 % 32.19 % 0 %
1 Year Return -67.45 % -14.88 % 63.34 % -43.67 % 49.24 % 0 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
BCLI VRTX ALNY REGN ARGX SGEN
Dividend Yield Percentage (TTM) - - - 0.47 % - -
Dividend Paid and Capex Coverage Ration (TTM) -5.63 % 11.09 % -0.43 % 4.37 % 65.28 % -5.87 %
Dividend Per Share (TTM) - - - 2.64 % - -
Payout Ratio (TTM) - - - 4.18 % - -
Growth
BCLI VRTX ALNY REGN ARGX SGEN
Asset Growth -56.46 % -0.87 %
Gross Profit Growth 420.38 % 10.25 %
Revenue Growth - 11.66 %
Revenue 3 Year - 45.6 %
Revenue 5 Year 174.48 % 163.93 %
Revenue 10 Year - 1632.15 %
EBIT Growth 32.84 % -93.69 %
Net Income Growth 167.61 % -114.8 %
Net Income 3 Yeari Growth Per Share 121.7 % -122.89 %
Net Income 5 Yeari Growth Per Share 116.05 % -145.38 %
Net Income 10 Yeari Growth Per Share 126.35 % 33.84 %
Operating Income Growth 45.46 % -106.08 %
Operating Cash Flow Growth (CFG) 55.55 % -113.93 %
Operating 3 Year CFG 84.19 % -118.65 %
Operating 5 Year CFG 74.04 % -131.3 %
Operating 10 Year CFG 57.51 % 12.43 %
EPS Growth 148.88 % -114.8 %
EPS Diluted Growth 148.88 % -114.97 %
Book Value Per Share -15.55 % -6.59 %
Share Holder 3 Year Equity Growth Per Share -118.33 % 62.6 %
Share Holder 5 Year Equity Growth Per Share 79.6 % 168.85 %
Share Holder 10 Year Equity Growth Per Share -124.38 % 1292.6 %
Dividend Per Share Growth - -
Dividend 3 Year Growth Per Share - -
Dividend 5 Year Growth Per Share - -
Dividend 10 Year Growth Per Share - -
Debt Growth 7.14 % 116.42 %
Free Cash Flow Growth 55.59 % -124.1 %
Updated On 31 Dec 2024 31 Dec 2024
Profitability
BCLI VRTX ALNY REGN ARGX SGEN
Gross Profit Margin TTM 61.48 % 86.11 % 83.64 % 81.98 % 65.82 % 79.1 %
Return on Assets TTM -446.14 % 15.13 % -6.99 % 11.67 % 15.06 % -16.61 %
Return on Equity TTM 167.52 % 22.14 % -274.21 % 15.11 % 18.96 % -20.8 %
Return on Capital Employed TTM 199.58 % 19.72 % -5.52 % 11.45 % 5.04 % -21.46 %
Net Income Per EBT TTM 100 % 83.16 % 84.06 % 91.46 % 237.3 % 101.33 %
EBT Per Ebit TTM 96.21 % 111.48 % 210.66 % 123.23 % 147.38 % 98.26 %
EBIT Per Revenue TTM -1401.53 % 34.36 % -7.32 % 27.83 % 13.47 % -31.24 %
Cash Flow To Debt Ratio TTM -1642.98 % 251.83 % -1.2 % 175.35 % 932.29 % -1043.73 %
Receivables Turnover TTM 8.01 6.03 4.34 2.53 1.91 3.91
Payables Turnover TTM 0.02 3.59 3.93 3.54 0.9 1.97
Inventory Turnover TTM - 1.06 5.62 0.8 2.26 0.96
Fixed Asset Turnover TTM 102.78 % 431.08 % 355.68 % 293.64 % 5009.77 % 665.41 %
Asset Turnover TTM 33.09 % 47.51 % 53.92 % 37.19 % 31.97 % 53.41 %
Operating Cash Flow Per Share TTM -1.1 14.98 -0.12 45.13 5.67 -2.46
Free Cash Flow Per Share TTM -1.1 13.63 -0.4 36.58 5.58 -2.88
Cash Per Share TTM 9.56 % 2486.48 % 2203.63 % 7107.14 % 5536.58 % 939.52 %
Operating Cash Flow Sales Ratio TTM -1116.61 % 33.68 % -0.63 % 33.37 % 17.54 % -23.12 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 90.99 % 335.21 % 81.05 % 98.47 % 117.04 %
Cash Flow Coverage Ratios TTM -1642.98 % 251.83 % -1.2 % 175.35 % 932.29 % -1043.73 %
Price To Free Cash Flows Ratio TTM -0.79 28.69 -1157.98 15.3 123.13 -81.26
Price To Operating Cash Flows Ratio TTM -0.65 26.14 -3840.08 12.51 140.63 -93.1
Price Cash Flow Ratio TTM -0.65 26.14 -3840.08 12.51 140.63 -93.1
Income Statement (TTM)
BCLI VRTX ALNY REGN ARGX SGEN
Revenue $0B $11.02B $2.25B $14.2B $2.19B $1.96B
Gross Profit $0B $9.49B $1.92B $11.75B $1.96B $1.55B
Gross Profit Ratio 100% 86.11% 85.62% 82.74% 89.62% 79.1%
EBITDA $-0.01B $0.49B $-0.18B $5.32B $0.11B $-0.62B
Net Income $0.01B $-0.54B $-0.28B $4.41B $0.83B $-0.61B
EPS Diluted 2.19 -2.08 -2.16 38.34 12.78 -3.3
Balance Sheet (MRQ)
BCLI VRTX ALNY REGN ARGX SGEN
Long Term Debt $0B $1.66B $1.25B $2.7B $0.03B $0.04B
Total Liabilities $0.01B $6.12B $4.17B $8.41B $0.7B $0.87B
Total Equity $-0.01B $16.41B $0.07B $29.35B $5.5B $2.8B
Total Investments $0B $6.65B $1.73B $15.42B $1.93B $1.42B
Total Debt $0B $1.75B $1.3B $2.7B $0.04B $0.04B
Total Assets $0B $22.53B $4.24B $37.76B $6.2B $3.67B
Cash Flow Statement (TTM)
BCLI VRTX ALNY REGN ARGX SGEN
Net Income $-0.01B $-0.54B $-0.28B $4.41B $0.83B $-0.61B
Inventory $0B $-0.52B $0.01B $-0.62B $-0.1B $-0.23B
Dividends Paid $0B $0B $0B $0B $0B $0B
Operating Cash Flow $-0.01B $-0.49B $-0.01B $4.42B $-0.08B $-0.45B
Capital Expenditure $0B $-0.3B $-0.03B $-0.76B $-0.07B $-0.08B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 36.72
AARD Aardvark Therapeutics, Inc. Common Stock 13.96
ABCL AbCellera Biologics Inc. 6.095
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.54
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 2.29
ABPWW 0.0324
ABSI Absci Corporation 4.995
ABUS Arbutus Biopharma Corporation 4.48
ABVC ABVC BioPharma, Inc. 2.892
ABVX Abivax SA American Depositary Shares 95.745
ACAD ACADIA Pharmaceuticals Inc. 21.735
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.9842
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 3.185
ACIU AC Immune SA 3.078
ETFs With Exposure to BCLI
Ticker ETF Name Weight Percentage Price
VTI Vanguard Total Stock Market Index Fund 0 328.35
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.00006 145.7
VXF Vanguard Extended Market Index Fund 0.00003 212.615
IWC iShares Micro-Cap ETF 0.00458 159.6
VITNX Vanguard Institutional Total Stock Market Index Fund Institutional Shares 0 111.18
VITPX Vanguard Institutional Total Stock Market Index Fund Institutional Plus Shares 0 111.16
STSB iShares Factors US Small Blend Style ETF 0.02 22.13
VTSAX Vanguard Total Stock Market Index Fund 0 159.12
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0.00003 160.36
VITSX Vanguard Total Stock Market Index Fund 0 159.14
SWTSX Schwab Total Stock Market Index Fd Select Shs a Series of Schwab Capit 0.000106985 16.12
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0.00003 160.38
AVSC Avantis U.S. Small Cap Equity ETF 0 57.93
VEMPX Vanguard Extended Market Index InstlPlus 0.00003 395.75
VSMPX Vanguard Total Stock Mkt Idx Instl Pls 0 298.53
Unlock